CRIS Current Research Information System

RICCI, ANGELA DALIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.930
NA - Nord America 1.775
EU - Europa 1.170
AF - Africa 128
SA - Sud America 117
OC - Oceania 2
Totale 5.122
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.758
SG - Singapore 732
CN - Cina 569
IT - Italia 223
SE - Svezia 206
VN - Vietnam 180
HK - Hong Kong 177
DE - Germania 169
GB - Regno Unito 124
IE - Irlanda 95
IN - India 89
KR - Corea 89
CH - Svizzera 86
BR - Brasile 82
NL - Olanda 75
FI - Finlandia 58
RU - Federazione Russa 56
CI - Costa d'Avorio 44
SC - Seychelles 32
JO - Giordania 24
ID - Indonesia 23
FR - Francia 22
TG - Togo 22
NG - Nigeria 16
AR - Argentina 15
AT - Austria 13
JP - Giappone 13
BG - Bulgaria 12
CA - Canada 10
TR - Turchia 8
PL - Polonia 7
MX - Messico 6
PY - Paraguay 6
ZA - Sudafrica 6
BE - Belgio 5
EC - Ecuador 5
PS - Palestinian Territory 5
CL - Cile 4
ES - Italia 4
IQ - Iraq 4
LT - Lituania 4
UA - Ucraina 4
BD - Bangladesh 3
AE - Emirati Arabi Uniti 2
CD - Congo 2
CO - Colombia 2
KE - Kenya 2
MA - Marocco 2
NZ - Nuova Zelanda 2
RS - Serbia 2
TH - Thailandia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AZ - Azerbaigian 1
CG - Congo 1
DK - Danimarca 1
DM - Dominica 1
HR - Croazia 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MY - Malesia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
Totale 5.122
Salva come PNG Salva come JPEG
Città #
Singapore 491
Dallas 208
Chandler 204
Hefei 202
Ashburn 196
Hong Kong 177
Princeton 97
Beijing 96
Santa Clara 94
Dublin 93
Seoul 87
Bern 83
Southend 81
Boardman 73
Fairfield 73
Bologna 67
Ho Chi Minh City 57
Hanoi 46
Abidjan 44
Los Angeles 41
New York 41
Helsinki 37
Houston 31
Redondo Beach 28
Seattle 27
Berlin 25
Florence 25
Amman 24
Lomé 22
Frankfurt am Main 19
Bengaluru 18
Buffalo 18
Redmond 17
Cambridge 16
Munich 16
London 15
Wilmington 15
Jakarta 14
Lappeenranta 14
San Diego 14
Woodbridge 14
São Paulo 13
Abeokuta 11
Milan 11
Turin 11
Shanghai 10
Sofia 10
Tokyo 10
Haiphong 9
Bühl 8
Chicago 8
Rome 8
Tongling 8
Boydton 7
Des Moines 7
Guangzhou 7
Hyderabad 7
Nuremberg 7
Turku 7
Ann Arbor 6
Falkenstein 6
Olalla 6
Vienna 6
Amsterdam 5
Brussels 5
Council Bluffs 5
Da Nang 5
Groningen 5
Halhul 5
Harbin 5
Medford 5
Montreal 5
Orem 5
San Francisco 5
Siena 5
Warsaw 5
Xi'an 5
Yubileyny 5
Zhengzhou 5
Boston 4
City of Westminster 4
Düsseldorf 4
Elk Grove Village 4
Fontanelice 4
Fulham 4
Guarulhos 4
Ninh Bình 4
Poplar 4
Quận Bình Thạnh 4
Stockholm 4
Tianjin 4
Ankara 3
Atlanta 3
Austin 3
Bexley 3
Brescia 3
Bắc Giang 3
Chiyoda-ku 3
Denver 3
Forlì 3
Totale 3.298
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 272
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 182
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 179
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 176
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 175
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 175
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 169
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 157
Bone targeting agents in patients with metastatic prostate cancer: State of the art 139
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 133
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 131
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 119
Hacking pancreatic cancer: Present and future of personalized medicine 119
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis 113
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 112
Experimental HER2- targeted therapies for biliary tract cancer 111
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 105
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 101
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 97
The functioning side of the pancreas: a review on insulinomas 96
Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications 90
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 89
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma 86
Nivolumab: an investigational agent for the treatment of biliary tract cancer 86
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 83
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 80
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 78
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer 77
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 75
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 75
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 73
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives 71
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art 69
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 68
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma 67
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 65
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives 65
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer 65
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives 58
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? 55
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future 52
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look 50
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies 48
Pd‐l1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer 45
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges 45
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): A new Pandora's box? 45
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 43
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 42
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? 42
Recent advances of immunotherapy for biliary tract cancer 41
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis 40
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” 40
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma 39
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait 38
DNA damage response alterations in gastric cancer: Knocking down a new wall 36
Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing 36
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? 34
Toward personalized therapy for cholangiocarcinoma: new insights and challenges 33
Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” 32
Immune-based combinations for advanced hepatocellular carcinoma: Shaping the direction of first-line therapy 14
Totale 5.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.208
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202187 0 0 0 0 0 5 8 12 23 13 4 22
2021/2022596 13 4 8 13 18 5 12 42 168 52 172 89
2022/20231.074 84 115 43 102 77 117 36 62 179 56 77 126
2023/2024309 58 41 20 22 25 50 20 20 6 27 11 9
2024/20251.284 61 190 151 102 142 61 76 44 13 93 99 252
2025/20261.844 321 389 469 229 311 125 0 0 0 0 0 0
Totale 5.260